IP Library Granted Patent US 8,475,767
Granted Patent B2
US 8,475,767 · App. 13/282,623 · Granted Jul 2, 2013

Anti-trypanosomal peptides and uses thereof

Inventors: John M. Harrington (Athens, GA); Stephen L. Hajduk (Athens, GA)
Assignee: University of George Research Foundation, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,475,767
App. No.
13/282,623
Granted
Jul 2, 2013
Kind
B2
Abstract

The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid protozoan with hydrophobic signal sequence peptides and compositions including such hydrophobic signal sequence peptides.

Claims (36)

1. A method of inducing rigidification of the plasma membrane of a bloodstream form of a kinetoplastid protozoan of the genus Trypanosoma , the method comprising contacting the protozoan with an isolated hydrophobic signal sequence peptide, wherein the isolated hydrophobic signal sequence peptide consists of 17 to 25 amino acid residues of an uncleaved, hydrophobic N-terminal signal sequence, wherein the isolated hydrophobic signal sequence peptide contains a positively charged amino acid at position minus five relative to the C-terminus of the hydrophobic signal sequence peptide, and wherein the hydrophobic signal sequence peptide comprises at least nine consecutive amino acid residues of MSDLGAVISLLLWGRQLFA, SEQ ID NO:1 or a derivative of SEQ ID NO:1, wherein the derivative of SEQ ID NO:1 has up to four hydrophobic amino acid residues of SEQ ID NO:1 exchanged for another hydrophobic amino acid, and/or one positively charged amino acid residues of SEQ ID NO:1 exchanged for another positively charged amino acid.

2. The method of claim 1 , wherein the hydrophobic signal sequence peptide is soluble in ethanol or dimethyl sulfoxide (DMSO).

3. A method of inducing rigidification of the plasma membrane of a bloodstream form of a kinetoplastid protozoan of the genus Trypanosoma , the method comprising contacting the protozoan with an isolated hydrophobic signal sequence peptide, wherein the isolated hydrophobic signal sequence peptide consists of 17 to 25 amino acid residues of an uncleaved, hydrophobic N-terminal signal sequence, wherein the isolated hydrophobic signal sequence peptide contains a positively charged amino acid at position minus five relative to the C-terminus of the hydrophobic signal sequence peptide, and wherein the hydrophobic signal sequence peptide comprises at least nine consecutive amino acid residues of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:15, SEQ ID NO:16 or SEQ ID NO:17.

4. The method of claim 1 , wherein the trypanosome is selected from the group consisting of Trypanosoma brucei brucei, T. b. gambiense , and T. b. rhodesiense, T. congolense , and T. vivax.

5. The method of claim 1 , wherein the hydrophobic signal sequence peptide is provided as a composition further comprising liposome, emulsion, or micelle.

6. The method of claim 1 , wherein the hydrophobic signal sequence peptide is provided as a composition further comprising an RNA aptamer that binds to a structurally conserved region of a trypanosome variant surface glycoprotein (VSG).

7. The method of claim 1 , wherein the hydrophobic signal sequence peptide is provided as a pyrogen-free composition.

8. The method of claim 1 , wherein the plasma membrane rigidification results in killing, inhibition of growth, inhibition of reproduction, plasma membrane degradation, and/or constricted cell motility of the bloodstream form of a kinetoplastid protozoan of the genus Trypanosoma.

9. The method of claim 1 wherein contacting the protozoan with a hydrophobic signal sequence peptide comprises in vitro, ex vivo, or in vivo contact.

10. The method of claim 9 comprising in vivo contact within the body of a mammalian subject.

11. A method of inducing rigidification of the plasma membrane of a bloodstream form of a kinetoplastid protozoan of the genus Trypanosoma , the method comprising contacting the protozoan with an isolated hydrophobic signal sequence peptide, wherein the isolated hydrophobic signal sequence peptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:15, SEQ ID NO:16 and SEQ ID NO:17.

12. A method of inducing rigidification of the plasma membrane of a bloodstream form of a kinetoplastid protozoan of the genus Trypanosoma , the method comprising contacting the protozoan with an isolated trypanocidal peptide of 12 to 25 amino acid residues in length, wherein the isolated trypanocidal peptide comprises at least nine consecutive amino acid residues of MSDLGAVISLLLWGRQLFA, SEQ ID NO:1 or a derivative of SEQ ID NO:1, wherein the derivative of SEQ ID NO:1 has up to four hydrophobic amino acid residues of SEQ ID NO:1 exchanged for another hydrophobic amino acid, and/or one positively charged amino acid residues of SEQ ID NO:1 exchanged for another positively charged amino acid.

13. The method of claim 3 , wherein the plasma membrane rigidification results in killing, inhibition of growth, inhibition of reproduction, plasma membrane degradation, and/or constricted cell motility of the bloodstream form of a kinetoplastid protozoan of the genus Trypanosoma.

14. The method of claim 3 , wherein the trypanosome is selected from the group consisting of Trypanosoma brucei brucei, T. b. gambiense , and T. b. rhodesiense, T. congolense , and T. vivax.

15. The method of claim 3 , wherein the hydrophobic signal sequence peptide is provided as a composition further comprising liposome, emulsion, or micelle.

16. The method of claim 3 , wherein the hydrophobic signal sequence peptide is provided as a composition further comprising an RNA aptamer that binds to a structurally conserved region of a trypanosome variant surface glycoprotein (VSG).

17. The method of claim 3 , wherein the hydrophobic signal sequence peptide is soluble in ethanol or dimethyl sulfoxide (DMSO).

18. The method of claim 3 , wherein the hydrophobic signal sequence peptide is provided as a pyrogen-free composition.

19. The method of claim 3 , wherein contacting the protozoan with a hydrophobic signal sequence peptide comprises in vitro, ex vivo, or in vivo contact.

20. The method of claim 19 comprising in vivo contact within the body of a mammalian subject.

21. The method of claim 11 , wherein the plasma membrane rigidification results in killing, inhibition of growth, inhibition of reproduction, plasma membrane degradation, and/or constricted cell motility of the bloodstream form of a kinetoplastid protozoan of the genus Trypanosoma.

22. The method of claim 11 , wherein the trypanosome is selected from the group consisting of Trypanosoma brucei brucei, T. b. gambiense , and T. b. rhodesiense, T. congolense , and T. vivax.

23. The method of claim 11 , wherein the hydrophobic signal sequence peptide is provided as a composition further comprising liposome, emulsion, or micelle.

24. The method of claim 11 , wherein the hydrophobic signal sequence peptide is provided as a composition further comprising an RNA aptamer that binds to a structurally conserved region of a trypanosome variant surface glycoprotein (VSG).

25. The method of claim 11 , wherein the hydrophobic signal sequence peptide is soluble in ethanol or dimethyl sulfoxide (DMSO).

26. The method of claim 11 , wherein the hydrophobic signal sequence peptide is provided as a pyrogen-free composition.

27. The method of claim 11 , wherein contacting the protozoan with a hydrophobic signal sequence peptide comprises in vitro, ex vivo, or in vivo contact.

28. The method of claim 27 comprising in vivo contact within the body of a mammalian subject.

29. The method of claim 12 , wherein the plasma membrane rigidification results in killing, inhibition of growth, inhibition of reproduction, plasma membrane degradation, and/or constricted cell motility of the bloodstream form of a kinetoplastid protozoan of the genus Trypanosoma.

30. The method of claim 12 , wherein the trypanosome is selected from the group consisting of Trypanosoma brucei brucei, T. b. gambiense , and T. b. rhodesiense, T. congolense , and T. vivax.

31. The method of claim 12 , wherein the hydrophobic signal sequence peptide is provided as a composition further comprising liposome, emulsion, or micelle.

32. The method of claim 12 , wherein the hydrophobic signal sequence peptide is provided as a composition further comprising an RNA aptamer that binds to a structurally conserved region of a trypanosome variant surface glycoprotein (VSG).

33. The method of claim 12 , wherein the hydrophobic signal sequence peptide is soluble in ethanol or dimethyl sulfoxide (DMSO).

34. The method of claim 12 , wherein the hydrophobic signal sequence peptide is provided as a pyrogen-free composition.

35. The method of claim 12 , wherein contacting the protozoan with a hydrophobic signal sequence peptide comprises in vitro, ex vivo, or in vivo contact.

36. The method of claim 35 comprising in vivo contact within the body of a mammalian subject.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2011
From: HARRINGTON, JOHN M.; HAJDUK, STEPHEN L.
To: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Reel/Frame 027324/0909 →
CONFIRMATORY LICENSE Recorded Nov 18, 2011
From: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027251/0152 →
Continuity (4)
Continuation In Part PCTUS2010032545 · Apr 27, 2010
Provisional Application 61172908 · Apr 27, 2009
Provisional Application 61317895 · Mar 26, 2010
Related Publication 20120070490A1 · Mar 22, 2012